David Ritchie

12.0k total citations
286 papers, 7.0k citations indexed

About

David Ritchie is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, David Ritchie has authored 286 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 128 papers in Hematology, 113 papers in Oncology and 86 papers in Immunology. Recurrent topics in David Ritchie's work include Hematopoietic Stem Cell Transplantation (65 papers), Immune Cell Function and Interaction (58 papers) and Lymphoma Diagnosis and Treatment (54 papers). David Ritchie is often cited by papers focused on Hematopoietic Stem Cell Transplantation (65 papers), Immune Cell Function and Interaction (58 papers) and Lymphoma Diagnosis and Treatment (54 papers). David Ritchie collaborates with scholars based in Australia, United States and New Zealand. David Ritchie's co-authors include H. Miles Prince, Paul J. Neeson, Mark J. Smyth, Simon J. Harrison, Hang Quach, John F. Seymour, Franca Ronchese, Ian F. Hermans, Rachel Koldej and Jianping Yang and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

David Ritchie

270 papers receiving 6.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Ritchie Australia	43	3.0k	2.8k	1.8k	1.6k	1.2k	286	7.0k
Marion Subklewe Germany	42	3.8k 1.3×	3.9k 1.4×	1.5k 0.8×	2.6k 1.6×	651 0.5×	167	8.4k
Jan W. Gratama Netherlands	48	3.7k 1.3×	2.1k 0.7×	1.1k 0.6×	1.6k 1.0×	904 0.7×	216	7.6k
Ingo G.H. Schmidt‐Wolf Germany	48	3.9k 1.3×	2.9k 1.0×	1.1k 0.6×	3.9k 2.4×	1.4k 1.1×	248	10.4k
Mine Harada Japan	49	2.7k 0.9×	3.7k 1.3×	2.7k 1.5×	2.4k 1.4×	850 0.7×	375	10.2k
Peter Bader Germany	50	2.6k 0.9×	2.6k 0.9×	5.3k 2.9×	1.4k 0.8×	631 0.5×	270	8.9k
Alan S. Wayne United States	39	4.4k 1.5×	2.4k 0.8×	2.3k 1.3×	1.9k 1.2×	558 0.5×	170	8.4k
Thomas Klingebiel Germany	55	3.1k 1.0×	2.6k 0.9×	4.3k 2.3×	1.5k 0.9×	558 0.5×	305	10.0k
Xiaoping Su United States	49	2.8k 1.0×	1.7k 0.6×	2.0k 1.1×	5.8k 3.5×	697 0.6×	171	12.1k
Hirokazu Kanegane Japan	44	2.1k 0.7×	4.0k 1.4×	1.7k 0.9×	1.3k 0.8×	887 0.7×	308	7.4k
Takanori Teshima Japan	52	2.5k 0.8×	5.0k 1.8×	5.6k 3.1×	1.8k 1.1×	643 0.5×	486	10.6k

Countries citing papers authored by David Ritchie

Since Specialization

Citations

This map shows the geographic impact of David Ritchie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Ritchie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Ritchie more than expected).

Fields of papers citing papers by David Ritchie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Ritchie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Ritchie. The network helps show where David Ritchie may publish in the future.

Co-authorship network of co-authors of David Ritchie

This figure shows the co-authorship network connecting the top 25 collaborators of David Ritchie. A scholar is included among the top collaborators of David Ritchie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Ritchie. David Ritchie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Barraclough, Allison, Sze Ting Lee, Melinda Burgess, et al.. (2025). Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study. Blood Advances. 9(6). 1432–1441.

Handunnetti, Sasanka M., Amit Khot, Piers Blombery, et al.. (2025). Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma. Blood Advances. 10(5). 1733–1742.

Handunnetti, Sasanka M., Mary Ann Anderson, Kate Burbury, et al.. (2024). Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions. Blood. 144(8). 867–872. 7 indexed citations

Shortt, Jake, Peter Galettis, Chan Y. Cheah, et al.. (2023). A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma. Clinical Epigenetics. 15(1). 15–15. 3 indexed citations

McEwan, Ashley, Matthew Greenwood, Christopher Wård, et al.. (2023). Diagnosis and management of endothelial disorders following haematopoietic stem cell transplantation. Internal Medicine Journal. 53(12). 2162–2174. 5 indexed citations

Lew, Thomas E., Edward R. Scheffer Cliff, Michael Dickinson, et al.. (2023). Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53 -mutated disease. Leukemia & lymphoma. 64(11). 1792–1800. 5 indexed citations

Loo, Sun, Richard Dillon, Adam Ivey, et al.. (2022). Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome. Blood. 140(22). 2407–2411. 42 indexed citations

Ferrer‐Font, Laura, R. J. Anderson, Benjamin J. Compton, et al.. (2022). Intratumoural administration of an NKT cell agonist with CpG promotes NKT cell infiltration associated with an enhanced antitumour response and abscopal effect. OncoImmunology. 11(1). 2081009–2081009. 6 indexed citations

Kennedy, Glen, Siok‐Keen Tey, Luke Buizen, et al.. (2021). A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis. Blood. 137(14). 1970–1979. 32 indexed citations

10.

Kiers, Lynette, et al.. (2021). Oromandibular parafunction in chronic graft‐versus‐host disease: novel association and treatment approach. Internal Medicine Journal. 51(11). 1950–1953. 2 indexed citations

11.

Lindsay, Julian, Jad Othman, Michelle K. Yong, et al.. (2021). Dynamics of Epstein–Barr virus on post‐transplant lymphoproliferative disorders after antithymocyte globulin‐conditioned allogeneic hematopoietic cell transplant. Transplant Infectious Disease. 23(5). e13719–e13719. 7 indexed citations

12.

Lewis, Katharine L., Preetesh Jain, Yun Qing, et al.. (2020). Autologous stem cell transplantation for untreated transformed indolent B‐cell lymphoma in first remission: an international, multi‐centre propensity‐score‐matched study. British Journal of Haematology. 191(5). 806–815. 7 indexed citations

13.

Douglas, Abby, Lijia Yu, Vijaya Sundararajan, et al.. (2020). The QuantiFERON Monitor^® assay is predictive of infection post allogeneic hematopoietic cell transplantation. Transplant Infectious Disease. 22(3). e13260–e13260. 13 indexed citations

14.

Trotman, Judith, Stephen Opat, Paula Marlton, et al.. (2019). PF481 UPDATED SAFETY AND EFFICACY DATA IN A PHASE 1/2 TRIAL OF PATIENTS WITH WALDENSTRÖM MACROGLOBULINAEMIA (WM) TREATED WITH THE BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB‐3111). HemaSphere. 3(S1). 192–193. 3 indexed citations

15.

Douglas, Abby, Caroline Marshall, Sarah L. Baines, et al.. (2019). Utilizing genomic analyses to investigate the first outbreak of van A vancomycin-resistant Enterococcus in Australia with emergence of daptomycin non-susceptibility. Journal of Medical Microbiology. 68(3). 303–308. 11 indexed citations

16.

Davenport, Alexander J., Ryan Cross, Katherine A. Watson, et al.. (2018). Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity. Proceedings of the National Academy of Sciences. 115(9). E2068–E2076. 244 indexed citations

17.

Gherardin, Nicholas A., Liyen Loh, Alexander J. Davenport, et al.. (2018). Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma. Scientific Reports. 8(1). 4159–4159. 77 indexed citations

18.

Davenport, Alexander J., Misty R. Jenkins, Ryan Cross, et al.. (2015). CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells. Cancer Immunology Research. 3(5). 483–494. 112 indexed citations

19.

Jones, Kimberley, Frank Vari, Colm Keane, et al.. (2012). Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma. Clinical Cancer Research. 19(3). 731–742. 83 indexed citations

20.

Breen, Sibilah, Sanchia Aranda, David Ritchie, et al.. (2012). IMPROVING THE MANAGEMENT OF CHEMOTHERAPY TOXICITIES IN HAEMATOLOGICAL CANCER PATIENTS: A PHASE II RANDOMISED CONTROLLED TRIAL OF THE PATIENT REMOTE INTERVENTION AND SYMPTOM MANAGEMENT SYSTEM (PRISMS). Discovery Research Portal (University of Dundee). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact